Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Debt to Equity (2016 - 2022)

Acro Biomedical has reported Debt to Equity over the past 7 years, most recently at $0.32 for Q4 2022.

  • Quarterly results put Debt to Equity at $0.32 for Q4 2022, up 402.99% from a year ago — trailing twelve months through Dec 2022 was $0.32 (up 402.99% YoY), and the annual figure for FY2022 was $0.32, up 402.99%.
  • Debt to Equity for Q4 2022 was $0.32 at Acro Biomedical, up from $0.16 in the prior quarter.
  • Over the last five years, Debt to Equity for ACBM hit a ceiling of $0.71 in Q4 2020 and a floor of $0.0 in Q4 2018.
  • Median Debt to Equity over the past 5 years was $0.09 (2019), compared with a mean of $0.15.
  • Biggest five-year swings in Debt to Equity: crashed 96.0% in 2018 and later skyrocketed 2051.95% in 2020.
  • Acro Biomedical's Debt to Equity stood at $0.0 in 2018, then soared by 1077.2% to $0.03 in 2019, then skyrocketed by 2051.95% to $0.71 in 2020, then plummeted by 90.9% to $0.06 in 2021, then soared by 402.99% to $0.32 in 2022.
  • The last three reported values for Debt to Equity were $0.32 (Q4 2022), $0.16 (Q3 2022), and $0.04 (Q2 2022) per Business Quant data.